|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZMIZ1 |
Gene summary for ZMIZ1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZMIZ1 | Gene ID | 57178 |
| Gene name | zinc finger MIZ-type containing 1 | |
| Gene Alias | MIZ | |
| Cytomap | 10q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0JLS3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57178 | ZMIZ1 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.10e-07 | 5.02e-01 | -0.1464 |
| 57178 | ZMIZ1 | HTA11_866_2000001011 | Human | Colorectum | AD | 3.38e-03 | 3.67e-01 | -0.1001 |
| 57178 | ZMIZ1 | A015-C-203 | Human | Colorectum | FAP | 7.20e-14 | -1.45e-01 | -0.1294 |
| 57178 | ZMIZ1 | A015-C-204 | Human | Colorectum | FAP | 2.10e-02 | -1.66e-01 | -0.0228 |
| 57178 | ZMIZ1 | A002-C-201 | Human | Colorectum | FAP | 4.61e-04 | -2.29e-02 | 0.0324 |
| 57178 | ZMIZ1 | A001-C-119 | Human | Colorectum | FAP | 1.34e-03 | -3.01e-01 | -0.1557 |
| 57178 | ZMIZ1 | A001-C-108 | Human | Colorectum | FAP | 4.68e-07 | -1.02e-01 | -0.0272 |
| 57178 | ZMIZ1 | A002-C-205 | Human | Colorectum | FAP | 4.12e-12 | -2.29e-01 | -0.1236 |
| 57178 | ZMIZ1 | A015-C-006 | Human | Colorectum | FAP | 2.83e-09 | -2.93e-01 | -0.0994 |
| 57178 | ZMIZ1 | A015-C-106 | Human | Colorectum | FAP | 2.19e-03 | 4.10e-03 | -0.0511 |
| 57178 | ZMIZ1 | A002-C-114 | Human | Colorectum | FAP | 9.12e-09 | -6.84e-02 | -0.1561 |
| 57178 | ZMIZ1 | A015-C-104 | Human | Colorectum | FAP | 5.91e-15 | -2.38e-01 | -0.1899 |
| 57178 | ZMIZ1 | A001-C-014 | Human | Colorectum | FAP | 3.18e-04 | -1.30e-01 | 0.0135 |
| 57178 | ZMIZ1 | A002-C-016 | Human | Colorectum | FAP | 2.43e-08 | -4.63e-02 | 0.0521 |
| 57178 | ZMIZ1 | A015-C-002 | Human | Colorectum | FAP | 1.63e-06 | -2.61e-01 | -0.0763 |
| 57178 | ZMIZ1 | A001-C-203 | Human | Colorectum | FAP | 2.09e-02 | -2.64e-02 | -0.0481 |
| 57178 | ZMIZ1 | A002-C-116 | Human | Colorectum | FAP | 1.91e-14 | -1.60e-01 | -0.0452 |
| 57178 | ZMIZ1 | A014-C-008 | Human | Colorectum | FAP | 1.83e-05 | -8.60e-02 | -0.191 |
| 57178 | ZMIZ1 | A018-E-020 | Human | Colorectum | FAP | 1.62e-09 | -1.93e-01 | -0.2034 |
| 57178 | ZMIZ1 | F034 | Human | Colorectum | FAP | 3.69e-07 | 7.15e-03 | -0.0665 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001692513 | Thyroid | ATC | protein sumoylation | 30/6293 | 53/18723 | 4.84e-04 | 2.83e-03 | 30 |
| GO:000721915 | Thyroid | ATC | Notch signaling pathway | 79/6293 | 172/18723 | 5.08e-04 | 2.96e-03 | 79 |
| GO:002198722 | Thyroid | ATC | cerebral cortex development | 55/6293 | 114/18723 | 8.32e-04 | 4.57e-03 | 55 |
| GO:004206323 | Thyroid | ATC | gliogenesis | 127/6293 | 301/18723 | 1.07e-03 | 5.66e-03 | 127 |
| GO:004809621 | Thyroid | ATC | chromatin-mediated maintenance of transcription | 9/6293 | 11/18723 | 1.46e-03 | 7.47e-03 | 9 |
| GO:00608401 | Thyroid | ATC | artery development | 48/6293 | 100/18723 | 1.97e-03 | 9.52e-03 | 48 |
| GO:0009755110 | Thyroid | ATC | hormone-mediated signaling pathway | 83/6293 | 190/18723 | 2.34e-03 | 1.09e-02 | 83 |
| GO:1903706112 | Thyroid | ATC | regulation of hemopoiesis | 148/6293 | 367/18723 | 3.87e-03 | 1.68e-02 | 148 |
| GO:00488441 | Thyroid | ATC | artery morphogenesis | 36/6293 | 74/18723 | 5.19e-03 | 2.12e-02 | 36 |
| GO:00083472 | Thyroid | ATC | glial cell migration | 27/6293 | 53/18723 | 6.76e-03 | 2.69e-02 | 27 |
| GO:00458152 | Thyroid | ATC | positive regulation of gene expression, epigenetic | 11/6293 | 17/18723 | 8.56e-03 | 3.26e-02 | 11 |
| GO:00218012 | Thyroid | ATC | cerebral cortex radial glia guided migration | 14/6293 | 24/18723 | 1.12e-02 | 4.00e-02 | 14 |
| GO:00220302 | Thyroid | ATC | telencephalon glial cell migration | 14/6293 | 24/18723 | 1.12e-02 | 4.00e-02 | 14 |
| GO:00085937 | Thyroid | ATC | regulation of Notch signaling pathway | 43/6293 | 95/18723 | 1.19e-02 | 4.22e-02 | 43 |
| GO:000157021 | Thyroid | ATC | vasculogenesis | 37/6293 | 80/18723 | 1.26e-02 | 4.42e-02 | 37 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ZMIZ1 | SMC | Cervix | Healthy | NAV2,HPCAL1,KCNMA1, etc. | 8.31e-01 |  |
| ZMIZ1 | STM | Thyroid | Healthy | NFAT5,NCOA3,HECA, etc. | 5.40e-01 |  |
| ZMIZ1 | STM | Thyroid | HT | KCNB1,RARRES1,AL359220.1, etc. | 6.94e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZMIZ1 | SNV | Missense_Mutation | novel | c.1350N>A | p.Met450Ile | p.M450I | Q9ULJ6 | protein_coding | tolerated(0.06) | benign(0.003) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
| ZMIZ1 | SNV | Missense_Mutation | c.901N>A | p.Ala301Thr | p.A301T | Q9ULJ6 | protein_coding | tolerated_low_confidence(0.05) | possibly_damaging(0.824) | TCGA-AC-A4ZE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZMIZ1 | SNV | Missense_Mutation | novel | c.1882G>A | p.Val628Met | p.V628M | Q9ULJ6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZMIZ1 | SNV | Missense_Mutation | rs751935868 | c.1606G>A | p.Val536Ile | p.V536I | Q9ULJ6 | protein_coding | tolerated(0.11) | benign(0.27) | TCGA-AN-A0XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZMIZ1 | SNV | Missense_Mutation | novel | c.558G>T | p.Met186Ile | p.M186I | Q9ULJ6 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.876) | TCGA-BH-A5IZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| ZMIZ1 | SNV | Missense_Mutation | c.2732N>G | p.Met911Arg | p.M911R | Q9ULJ6 | protein_coding | deleterious_low_confidence(0.03) | benign(0.391) | TCGA-C8-A134-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| ZMIZ1 | SNV | Missense_Mutation | c.2191N>T | p.Val731Leu | p.V731L | Q9ULJ6 | protein_coding | deleterious(0.05) | benign(0.065) | TCGA-EW-A1J2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
| ZMIZ1 | SNV | Missense_Mutation | novel | c.1795N>G | p.Thr599Ala | p.T599A | Q9ULJ6 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-EW-A6SB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZMIZ1 | insertion | Frame_Shift_Ins | novel | c.2737_2738insGGCTCACACCTGTAATCCCAGC | p.Asp913GlyfsTer48 | p.D913Gfs*48 | Q9ULJ6 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ZMIZ1 | deletion | Frame_Shift_Del | c.608delG | p.Gly203AlafsTer2 | p.G203Afs*2 | Q9ULJ6 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |